Evidence map›Paper›PMID 34985998›Full record

ArticleJournal of virology2022

Antiviral CD19

Nisha R Dhanushkodi, Swayam Prakash, Ruchi Srivastava, Pierre-Gregoire A Coulon, Danielle Arellano, Rayomand V Kapadia, Raian Fahim, Berfin Suzer, Leila Jamal, Hawa Vahed and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nisha R DhanushkodiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Swayam PrakashLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Ruchi SrivastavaLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Pierre-Gregoire A CoulonLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Danielle ArellanoLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Rayomand V KapadiaLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Raian FahimLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Berfin SuzerLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Leila JamalLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.
Hawa VahedDepartment of Vaccines and Immunotherapies, TechImmune, LLC, University Lab Partners, Irvine, California, USA.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, USA.ORCID 0000-0001-9468-2521
University of California, Irvine · US

Funding

Therapeutic Ocular HSV Vaccine in HLA Transgenic RabbitsR01EY019896 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2010 to 2025
$5.1M
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital HerpesR01AI150091 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lbachir BenMohamed · 2020 to 2026
$4.0M
Ocular Mucsoal Immunity Induced by HSV-1 LipopeptidesR01EY014900 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2003 to 2014
$3.1M
Mucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4M
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic DiseaseR01EY026103 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2016 to 2019
$1.5M
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular HerpeR01EY024618 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2014 to 2016
$1.2M
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464k
LAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425k
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLESR21AI147499 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$399k
A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINER41AI138764 · NIAID · SUNOMIX THERAPEUTICS · PI BENMOHAMED, LBACHIR · 2018 to 2018
$236k
A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINER43AI124911 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2016 to 2016
$225k
NEI NIH HHS R01 EY014900NEI NIH HHS R01 EY019896NEI NIH HHS R01 EY024618NEI NIH HHS R01 EY026103NIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI150091NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326NIAID NIH HHS R21 AI147499NIAID NIH HHS R41 AI138764NIAID NIH HHS R43 AI124911
6 · The paper itself

Abstract

Reactivation of herpes simplex virus 1 (HSV-1) from latently infected neurons of the trigeminal ganglia (TG) leads to blinding recurrent herpetic disease in symptomatic (SYMP) individuals. Although the role of T cells in herpes immunity seen in asymptomatic (ASYMP) individuals is heavily explored, the role of B cells is less investigated. In the present study, we evaluated whether B cells are associated with protective immunity against recurrent ocular herpes. The frequencies of circulating HSV-specific memory B cells and of memory follicular helper T cells (CD4

Indexed as

Herpes SimplexHerpesvirus 1, HumanKeratitis, HerpeticMemory B CellsReinfectionAnimalsAntigens, CD19ImmunityImmunoglobulin AImmunoglobulin GMiceTrigeminal GanglionTumor Necrosis Factor Receptor Superfamily, Member 7Virus ActivationAntigens, CD19Immunoglobulin AImmunoglobulin GTumor Necrosis Factor Receptor Superfamily, Member 7asymptomatic herpesB memory cellsocular herpesplasma cellsvirus-specific B cell

Identifiers

PMID34985998
PMCPMC8906405
OpenAlexW4220783881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.